Gene-Guided drug dosing after kidney transplant: a step toward personalized care

NCT ID NCT00552201

First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 23 times

Summary

This study looked at whether using a patient's genetic information to set the starting dose of tacrolimus (an anti-rejection drug) leads to better drug levels in the blood after a kidney transplant. 280 adults receiving a kidney transplant were randomly assigned to get either a standard dose or a dose based on their CYP3A5 gene. The goal was to see if the gene-based approach helped more patients reach the target drug level faster. The study lasted 3 months per patient.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU Angers

    Angers, France

  • CHU Gabriel Montpied

    Clermont-Ferrand, 63003, France

  • CHU Limoges - Hôpital Dupuytren

    Limoges, 87042, France

  • CHU Poitiers- hôpital Jean Bernard

    Poitiers, 86021, France

  • CHU Reims - Hôpital Maison Blanche

    Reims, 51092, France

  • CHU Rennes - Hôpital Pontchaillou

    Rennes, 35033, France

  • CHU Rouen - Hôpital de Bois-Guillaume

    Bois-Guillaume, 76230, France

  • CHU Strasbourg - Hospices Civils

    Strasbourg, 67091, France

  • CHU Tours - Hôpital Bretonneau

    Tours, 37044, France

  • CHU de la côté de Nacre

    Caen, 14033, France

Conditions

Explore the condition pages connected to this study.